Prix et remboursements. As an example in Europe in 2015 92%[3] of the documented B influenza cases were caused by the B/Victoria strain not included in the vaccine. De nombreux appels à rendre le vaccin obligatoire pour une certaine catégorie de population se sont faits entendre depuis la rentrée. Since then, influenza vaccines have been trivalent to help protect against three strains of influenza virus: a type A(H1N1), a type A(H3N2) and one type B. Si vous ou votre enfant n'avez pas été vacciné durant l'automne, il est encore possible de lêtre jusqu'au printemps car vous ou votre enfant courez le risque de contracter la grippe jusqu'à cette période. Au vu des données disponibles, la Commission considère que VAXIGRIPTETRA napporte pas damélioration du service médical rendu (ASMR V) par rapport aux vaccins trivalents inactivés disponibles indiqués dans la prévention de la grippe (cf. 1. Sanofi Pasteur, the vaccines division of Sanofi, announced today that its quadrivalent influenza vaccine VaxigripTetra™ obtained a positive end of procedure from the German Reference Member State Paul Ehrlich Institute, as a conclusion of the European Decentralized Procedure. > virus de la grippe fragmenté, inactivé, souche A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09 - souche analogue (A/Guangdong-Maonan/SWL1536/2019, CNIC-1909), > virus de la grippe fragmenté, inactivé, souche A/Hong Kong/2671/2019 (H3N2) - souche analogue (A/Hong Kong/2671/2019, IVR-208), > virus de la grippe fragmenté, inactivé, souche B/Washington/02/2019 - souche analogue (B/Washington/02/2019, type sauvage), > Virus de la grippe fragmenté, inactivé, souche B/Phuket/3073/2013 - souche analogue (B/Phuket/3073/2013, type sauvage), Titulaire de l'autorisation : SANOFI PASTEUR, Conditions de prescription et de délivrance : Aucune, Type de procédure :
Dans un communiqué du 4 novembre, l’Agence nationale de l’assurance-maladie (ANAM) a annoncé que le vaccin contre la grippe saisonnière a intègré le guide des médicaments remboursables. La campagne nationale de vaccination contre la grippe saisonnière se déroule du 13 octobre 2020 au 31 janvier 2021. VAXIGRIP est un vaccin. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). However, since the 2001-2002 season, influenza B viruses have diverged into two antigenically distinct lineages (the Victoria and Yamagata lineages). Un patient se fait vacciner à Paris, en septembre 2009 (PHOTO D'ILLUSTRATION). Currently seasonal influenza vaccination prevents on average between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths every year[12]. Each winter the strains for the seasonal influenza vaccines are selected from the influenza strains anticipated to circulate in the Northern Hemisphere during the approaching influenza season by WHO. VAXIGRIP doit être utilisé selon les recommandations officielles.Lorsqu’une personne reçoit le vaccin VAXIGRIP, le système immunitaire (le système de défense naturelle de l’organisme) développe sa propre protection (anticorps) contre la maladie. However, two distinct influenza B strains (B/Victoria and B/Yamagata) now co-circulate worldwide in varying and unpredictable proportions[1]. Berne About the evolution of influenza vaccines. VaxigripTetra Admission 01.08.2018 (PDF, 147 kB, 12.09.2018) Admissions et modifications de limitation effectuées depuis le 1er juillet 2018 Afstyla Admission 01.07.2018 (PDF, 119 kB, 03.02.2020) Sanofi Pasteur intends to progressively switch all its trivalent influenza vaccines to quadrivalent influenza vaccines worldwide. Lorsquune personne reçoit VaxigripTetra, le système immunitaire (le système de défense naturelle de lorganisme) développe sa propre protection (anticorps) contre la maladie. . These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. The World Health Organization includes quadrivalent influenza vaccines in its recommendations, stating "Quadrivalent influenza vaccines that could potentially provide wider protection against influenza B viruses are becoming available and recommendations should not be limited to trivalent vaccine." +41 58 462 90 35 "For over 60 years the expertise of Sanofi Pasteur has been committed to providing new immunization solutions for the prevention of influenza to better protect lives and help healthcare providers meet the specific immunization needs of all types of their patients.